Dashboard
Manage Tickers

BIIB


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

how-is-the-market-feeling-about-biogen
How Is The Market Feeling About Biogen?
05/20/2024 20:45:13

truist-securities-maintains-buy-on-biogen-maintains-340-price-target
Truist Securities Maintains Buy on Biogen,...
05/16/2024 17:14:29

Truist Securities analyst Robyn Karnauskas maintains Biogen (NASDAQ:BIIB) with a Buy and maintains $340 price target.

tale-of-two-ionis-partnered-neurology-focused-early-stage-assets-biogen-discontinues-one-decides-not-to-exercise-licensing-option-for-another
Tale Of Two Ionis-Partnered Neurology-Focu...
05/16/2024 16:11:55

Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on k...

Core News & Articles
Ionis And Biogen Say Development Of BIIB10...
05/16/2024 11:36:34

Core News & Articles
Reported Earlier, Biogen And Eisai Initiat...
05/15/2024 06:51:14

LEQEMBI is now approved in the U.S., Japan and China, and applications have been submitted for review in the European Union, Au...

jim-cramer-likes-micron-and-its-ceo-recommends-buying-this-big-bank
Jim Cramer Likes Micron And Its CEO, Recom...
05/13/2024 13:15:02

Jim Cramer recommends buying Micron, adding that he likes the company's CEO Sanjay Mehrotra. As for Fidelis? "Not a fav...

hsbc-maintains-buy-on-biogen-raises-price-target-to-342
HSBC Maintains Buy on Biogen, Raises Price...
05/03/2024 18:41:12

HSBC analyst Morten Herholdt maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $339 to $342.

the-analyst-landscape-27-takes-on-biogen
The Analyst Landscape: 27 Takes On Biogen
04/29/2024 17:01:07

oppenheimer-maintains-outperform-on-biogen-maintains-270-price-target
Oppenheimer Maintains Outperform on Biogen...
04/29/2024 16:49:51

Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:BIIB) with a Outperform and maintains $270 price target.

will-earnings-cheer-continue-to-buoy-markets-apple-amazon-pfizer-coinbase-lead-flurry-of-q1-reports-this-week
Will Earnings Cheer Continue To Buoy Marke...
04/29/2024 05:51:21

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...

barclays-maintains-equal-weight-on-biogen-lowers-price-target-to-200
Barclays Maintains Equal-Weight on Biogen,...
04/25/2024 18:02:40

Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $215 to $200.

these-analysts-revise-their-forecasts-on-biogen-after-q1-results
These Analysts Revise Their Forecasts On B...
04/25/2024 12:53:14

meta-platforms-to-rally-around-14-here-are-10-top-analyst-forecasts-for-thursday
Meta Platforms To Rally Around 14%? Here A...
04/25/2024 12:44:41

wedbush-maintains-neutral-on-biogen-raises-price-target-to-215
Wedbush Maintains Neutral on Biogen, Raise...
04/25/2024 12:33:01

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $213 to $215.

hc-wainwright--co-maintains-buy-on-biogen-lowers-price-target-to-300
HC Wainwright & Co. Maintains Buy on Bioge...
04/25/2024 11:53:17

HC Wainwright & Co. analyst Andrew Fein maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $325 ...

needham-reiterates-buy-on-biogen-maintains-294-price-target
Needham Reiterates Buy on Biogen, Maintain...
04/25/2024 09:33:02

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $294 price target.

biogeneisais-popular-alzheimers-drug-leqembi-is-seeing-slow-adoption---heres-why
Biogen/Eisai's Popular Alzheimer's Drug Le...
04/24/2024 18:23:08

Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and ...

treasury-yields-rise-tesla-jumps-on-cheaper-model-pledge-yen-plummets-to-34-year-lows-whats-driving-markets-wednesday
Treasury Yields Rise, Tesla Jumps On Cheap...
04/24/2024 17:40:39

Rising Treasury yields have investors cautious despite positive news from the earnings season. The yield on the long-dated 3...

biogens-leqembi-commercial-ramp-up-modest-but-up-ticking-reports-mixed-bag-q1-earnings
Biogen's Leqembi Commercial Ramp-Up Modest...
04/24/2024 16:12:52

Biogen reports Q1 results: adjusted EPS $3.67 (beat consensus), sales $2.29 billion (missed consensus). Leqembi launch uptake t...

needham-reiterates-buy-on-biogen-maintains-294-price-target
Needham Reiterates Buy on Biogen, Maintain...
04/24/2024 12:34:17

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $294 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION